Big Pharmas Amgen, BMS shield BigHat from stormy market with $75M funding

BigHat Biosciences just capped off an $75 million series B to design safer, more effective antibody therapies, with Big Pharmas Amgen and Bristol Myers Squibb both joining the round as new investors.